vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and Relay Therapeutics, Inc. (RLAY). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $7.0M, roughly 1.3× Relay Therapeutics, Inc.). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-235.9M).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
Relay Therapeutics is a clinical-stage biotechnology company focused on developing precision oncology therapies. It leverages advanced computational modeling of protein dynamics, paired with cutting-edge experimental biology, to design targeted medicines for previously intractable cancer types, serving global oncology care markets and patient populations.
PLX vs RLAY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $7.0M |
| Net Profit | $-5.5M | — |
| Gross Margin | 49.4% | — |
| Operating Margin | -51.1% | — |
| Net Margin | -60.3% | — |
| Revenue YoY | -49.9% | — |
| Net Profit YoY | -184.8% | — |
| EPS (diluted) | $-0.06 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $7.0M | ||
| Q3 25 | $17.9M | $0 | ||
| Q2 25 | $15.7M | — | ||
| Q1 25 | $10.1M | $7.7M | ||
| Q4 24 | $18.2M | $0 | ||
| Q3 24 | $18.0M | $0 | ||
| Q2 24 | $13.5M | $0 | ||
| Q1 24 | — | $10.0M |
| Q4 25 | $-5.5M | — | ||
| Q3 25 | $2.4M | $-74.1M | ||
| Q2 25 | $164.0K | — | ||
| Q1 25 | $-3.6M | $-77.1M | ||
| Q4 24 | $6.5M | — | ||
| Q3 24 | $3.2M | $-88.1M | ||
| Q2 24 | $-2.2M | $-92.2M | ||
| Q1 24 | — | $-81.4M |
| Q4 25 | 49.4% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 62.5% | — | ||
| Q1 25 | 19.1% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q1 24 | — | — |
| Q4 25 | -51.1% | — | ||
| Q3 25 | 11.9% | — | ||
| Q2 25 | 7.5% | — | ||
| Q1 25 | -41.0% | -1105.2% | ||
| Q4 24 | 39.6% | — | ||
| Q3 24 | 22.2% | — | ||
| Q2 24 | -18.0% | — | ||
| Q1 24 | — | -903.0% |
| Q4 25 | -60.3% | — | ||
| Q3 25 | 13.2% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | -35.8% | -1003.6% | ||
| Q4 24 | 35.6% | — | ||
| Q3 24 | 18.0% | — | ||
| Q2 24 | -16.4% | — | ||
| Q1 24 | — | -813.3% |
| Q4 25 | $-0.06 | — | ||
| Q3 25 | $0.03 | $-0.43 | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $-0.05 | $-0.46 | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $0.03 | $-0.63 | ||
| Q2 24 | $-0.03 | $-0.69 | ||
| Q1 24 | — | $-0.62 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $84.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $567.1M |
| Total Assets | $82.3M | $621.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $84.0M | ||
| Q3 25 | $13.6M | $91.6M | ||
| Q2 25 | $17.9M | — | ||
| Q1 25 | $19.5M | $93.5M | ||
| Q4 24 | $19.8M | $124.3M | ||
| Q3 24 | $27.4M | $152.4M | ||
| Q2 24 | $23.4M | $134.1M | ||
| Q1 24 | — | $152.9M |
| Q4 25 | $48.2M | $567.1M | ||
| Q3 25 | $52.9M | $607.7M | ||
| Q2 25 | $49.9M | — | ||
| Q1 25 | $45.2M | $721.1M | ||
| Q4 24 | $43.2M | $777.8M | ||
| Q3 24 | $32.4M | $838.9M | ||
| Q2 24 | $28.6M | $681.7M | ||
| Q1 24 | — | $745.8M |
| Q4 25 | $82.3M | $621.3M | ||
| Q3 25 | $82.3M | $670.0M | ||
| Q2 25 | $78.5M | — | ||
| Q1 25 | $73.9M | $799.4M | ||
| Q4 24 | $73.4M | $871.3M | ||
| Q3 24 | $61.6M | $930.1M | ||
| Q2 24 | $91.5M | $772.5M | ||
| Q1 24 | — | $841.4M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-235.5M |
| Free Cash FlowOCF − Capex | $1.6M | $-235.9M |
| FCF MarginFCF / Revenue | 17.8% | -3370.0% |
| Capex IntensityCapex / Revenue | 4.4% | 5.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $-622.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-235.5M | ||
| Q3 25 | $-3.7M | $-62.1M | ||
| Q2 25 | $-5.2M | — | ||
| Q1 25 | $-5.1M | $-73.2M | ||
| Q4 24 | $4.0M | $-249.1M | ||
| Q3 24 | $4.1M | $-75.1M | ||
| Q2 24 | $-3.6M | $-65.8M | ||
| Q1 24 | — | $-50.3M |
| Q4 25 | $1.6M | $-235.9M | ||
| Q3 25 | $-4.2M | $-62.1M | ||
| Q2 25 | $-5.7M | — | ||
| Q1 25 | $-5.4M | $-73.6M | ||
| Q4 24 | $3.6M | $-251.1M | ||
| Q3 24 | $4.0M | $-75.3M | ||
| Q2 24 | $-3.8M | $-65.8M | ||
| Q1 24 | — | $-52.1M |
| Q4 25 | 17.8% | -3370.0% | ||
| Q3 25 | -23.7% | — | ||
| Q2 25 | -36.2% | — | ||
| Q1 25 | -53.0% | -958.4% | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | -28.1% | — | ||
| Q1 24 | — | -520.7% |
| Q4 25 | 4.4% | 5.9% | ||
| Q3 25 | 2.8% | — | ||
| Q2 25 | 2.8% | — | ||
| Q1 25 | 3.0% | 5.0% | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.3% | — | ||
| Q1 24 | — | 17.8% |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
RLAY
Segment breakdown not available.
